Treatment of multiple myeloma bone disease: experimental and clinical data. Papamerkouriou YM et al. Expert Opin Biol Ther. 2014 Nov 12:1-18. [Epub ahead of print]. Bisphosphonates in multiple myeloma: a fractured consensus. Kumar SK. Leuk Lymphoma. 2014 Nov 5:1-2. [Epub ahead of print]. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Berenson JR et al. Support Care…
DetailsThe potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods. Kontodimopoulos N. Qual Life Res. 2014 Nov 13. [Epub ahead of print]. Prevalence of monoclonal gammopathy in HIV patients in 2014. Genet P et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19649. doi: 10.7448/IAS.17.4.19649. eCollection 2014.…
DetailsCarfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. Sullivan MR et al. J Clin Apher. 2014 Nov 21. doi: 10.1002/jca.21371. [Epub ahead of print]. A case of endocapillary proliferative glomerulonephritis with macrophages phagocytosing monoclonal immunoglobulin lambda light chain. Watanabe H et al. Pathol Int. 2014 Nov 19. doi: 10.1111/pin.12229. [Epub ahead of print]. Successful re-administration of lenalidomide after lenalidomide-induced…
DetailsSubcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Ong SY et al. Br J Haematol. 2014 Nov 21. doi: 10.1111/bjh.13238. [Epub ahead of print]. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Clark RE et al. Blood…
DetailsIn this guidance NICE outlines recommendations for the use of erythropoiesis-stimulating agents for the treatment of anaemia in cancer patients undergoing chemotherapy.
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Mathis S et al. Cytometry B Clin Cytom. 2014 Oct 28. doi: 10.1002/cytob.21200. [Epub ahead of print]. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of…
DetailsUnveiling Skeletal Fragility in Patients Diagnosed with MGUS: No Longer a Condition of Undetermined Significance? Drake MT. J Bone Miner Res. 2014 Oct 15. doi: 10.1002/jbmr.2387. [Epub ahead of print]. A systemic disease un…suspected by physical examination. Costa C et al. BMJ Case Rep. 2014 Oct 9;2014. pii: bcr2014205919. doi: 10.1136/bcr-2014-205919. How I treat smoldering…
DetailsPanobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma candidates to autologous transplant. Mangiacavalli S et al. Leuk Lymphoma. 2014 Oct 27:1-8. [Epub ahead of print]. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Lau IJ…
DetailsImmune impairments in multiple myeloma bone marrow mesenchymal stromal cells. André T et al. Cancer Immunol Immunother. 2014 Oct 24. [Epub ahead of print]. Inhibition of Akt-signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. van der Waart AB et al. Blood. 2014 Oct 21. pii: blood-2014-05-578583. [Epub ahead of print]. Global…
DetailsPegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Cerchione C et al. Support Care Cancer. 2014 Oct 24. [Epub ahead of print]. Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma. Oksman MJ et al. Bone Marrow Transplant. 2014 Oct…
Details